Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact Us
Early Edition  //  Current Issue  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited

Medicine Research ›› 2023, Vol. 7 ›› Issue (3-4): 230007-230007.DOI: 10.21127/yaoyimr20230007

• Reports • Previous Articles     Next Articles

A Novel Combined Nanoparticle Delivery of Poly(ADP-Ribose) Polymerase Inhibitor-Olaparib and Copper Complexes for Chemosensitization Therapy in Breast Cancer

Xiaoya Huang, Kehai Liu*   

  1. Department of Biopharmaceutical Sciences, Shanghai Ocean University, Shanghai 201306, China
  • Received:2023-09-22 Revised:2023-10-20 Accepted:2023-10-30 Online:2023-12-20 Published:2024-02-22
  • Contact: * Email: khliu@shou.edu.cn (K. L.)

Abstract: Chemo-sensitization therapy has gained importance in the field of anti-cancer treatment in recent years. The combination of both chemotherapy and chemosensitization has unique advantages. However, there has been relatively limited research on combination treatment using metal complexes and chemosensitizers. Herein, we reports a two-drug synergistic delivery system combining a copper complex and a chemosensitizer Olaparib in a certain ratio of safety and efficiency is the key. Polyethylenimine (PEI) was chemically-linked to activated chemosensitizer Olaparib, which was connected to a bifunctional peptide, T15, for facilitation and nuclear targeting, resulting in Ola-PEI-T15. Then, a novel metal complex Cu/Ola-PEI-T15 was obtained by Cu2+ coordination to Ola-PEI-T15. The two therapeutic agents can be transported into the cells at the same time, giving full play to the synergistic anti-tumor effect.

Key words: chemosensitization, olaparib, metal complex, synergistic anti-tumor effect

Copyright © Medicine Research, All Rights Reserved.
Address: 425 East 76th Street, Apt 9E, New York, NY, 10021, United States